# Nasus Pharma Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Nasus Pharma Ltd). ## Overview Nasus Pharma Ltd is a clinical-stage pharmaceutical company focused on developing innovative intranasal drug products. The company is based in Tel Aviv, Israel and is organized around a proprietary intranasal technology platform and a pipeline of powder-based therapeutic candidates. ## Products & services • NS002 powder-based intranasal epinephrine candidate • Intranasal powder-based drug development platform • Pipeline of intranasal therapeutic programs • Clinical development and regulatory advancement services - **NS002** (0%) — A powder-based intranasal epinephrine product candidate being developed for allergic reaction treatment. - **Intranasal platform programs** (0%) — Additional proprietary intranasal powder-based programs targeting other therapeutic areas. - **Clinical development** (100%) — Preclinical, clinical, and regulatory work required to advance product candidates toward approval. - NS002 powder-based intranasal epinephrine candidate - Intranasal powder-based drug development platform - Pipeline of intranasal therapeutic programs - Clinical development and regulatory advancement services ## Customers Nasus Pharma does not sell commercial products broadly; its direct counterparties are primarily investors, clinical research vendors, and regulatory stakeholders. The eventual customers for its products would be patients, physicians, and healthcare providers that use intranasal treatments for conditions where rapid administration is clinically valuable. - **Capital providers** (primary) — Investors and financing counterparties that fund ongoing development and platform expansion. - **Clinical development partners** (primary) — CROs, laboratories, and consultants that support trials, manufacturing, and regulatory work. - **Regulators** (secondary) — Agencies that review clinical data and NDA submissions for NS002 and related programs. - **Future healthcare customers** (emerging) — Patients, physicians, and healthcare systems that could use approved intranasal products. - Equity investors funding clinical development - Clinical trial vendors and research contractors - Regulatory authorities evaluating product filings - Patients and physicians as eventual end-users - Healthcare providers needing rapid intranasal therapy ## Geography The company is incorporated as a foreign private issuer with principal executive offices in Tel Aviv, Israel and trades in the United States on the NYSE. Its development work is centered around its Israeli base, while its capital markets access and future commercialization pathway are tied to the U.S. pharmaceutical market. - Headquartered in Tel Aviv, Israel - Listed on the NYSE in the United States - Development and management functions based in Israel - U.S. capital markets are an important funding source - Future product commercialization is likely to be international ## Strategy Nasus Pharma's strategy is to advance NS002 toward pivotal study and NDA submission while broadening its intranasal platform into additional therapeutic areas. The company is trying to build a differentiated product family around powder-based intranasal administration, where faster or more convenient delivery could create clinical value versus existing options. - **Advance NS002 into pivotal study** (short-term) — Clinical proof and regulatory progress are the key value drivers for a single-asset biotech platform. - **Expand the intranasal pipeline** (medium-term) — A broader pipeline can reduce dependence on one candidate and increase platform optionality. - **Strengthen capital runway** (short-term) — Clinical-stage development requires sustained funding before any product revenue exists. - Advance NS002 through pivotal study and NDA preparation - Expand the intranasal powder-based product pipeline - Use the proprietary platform across new therapeutic areas - Maintain funding visibility for development programs - Differentiate through intranasal administration advantages ## Risks Nasus Pharma faces the typical risks of a clinical-stage pharmaceutical company: trial failure, regulatory delay, and the possibility that the product profile does not translate into approval or adoption. As a single-platform developer, it is also exposed to financing risk, concentration in a limited number of candidates, and execution risk across manufacturing, clinical operations, and NDA preparation. - **Clinical failure of NS002** [critical] — The business case depends on positive pivotal data and eventual approval for its lead candidate. - **Regulatory delay or rejection** [high] — FDA review outcomes can materially affect timing, cost, and the chance of market entry. - **Financing dependence** [high] — Clinical-stage operations require recurring capital before any meaningful product sales exist. - **Pipeline concentration** [high] — A narrow portfolio means setbacks in one program can disproportionately affect enterprise value. - Clinical trial results may not support approval - Regulatory review could delay or block NDA filing - Single-product concentration increases development risk - External funding is required before commercialization - Manufacturing and clinical execution are highly specialized ## Accounting Nasus Pharma's accounting is dominated by development-stage judgments rather than product revenue recognition. Investors should focus on the treatment of research and development expenses, share-based compensation, financing costs, and any discontinued operations related to Taffix, because these items can materially affect reported losses and comparability across periods. - **Discontinued operations** — Changes reported loss and segment presentation - **Share-based compensation** — Raises reported operating expenses - **Financing costs and warrants** — Affects equity, expenses, and dilution - **R&D expense timing** — Creates period-to-period volatility - Research and development expense recognition - Share-based compensation for employees and consultants - Private placement and warrant-related financing costs - Discontinued operations presentation for Taffix - Cash burn and capitalized deferred issuance costs --- *Last updated: 2026-09-28T12:13:23.558817+00:00*